ArticleFluids and barriers of the CNS2011
Detection of cancer cells in the cerebrospinal fluid: current methods and future directions.
Article in Fluids and barriers of the CNS, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 116 citations in OpenAlex.
- Pooled it
- Trial
- CSF CA 15-3 in breast cancer-related leptomeningeal metastases.Journal of neuro-oncology · 2014Trial
- Cerebrospinal Fluid in Pediatric Neuro-Oncology: Molecular Diagnosis, Disease Monitoring, and Clinical Translation.International journal of molecular sciences · 2026Review
- Utility and performance of cerebrospinal fluid cytology in discriminating central nervous system infections and brain tumors.Journal of neuro-oncology · 2025Article
- Investigation of GD2 synthase as a potential marker for retinoblastoma poor prognosis.Molecular biology reports · 2025Article
- Improved diagnostic accuracy for leptomeningeal dissemination in pediatric brain tumors using contrast-enhanced FLAIR imaging.Neuro-oncology practice · 2025Article
- Liquid biopsy for evaluating mutations and chromosomal aberrations in cerebrospinal fluid from patients with primary or metastatic CNS tumors.The journal of liquid biopsy · 2024Article
- Deep Proteome Analysis of Cerebrospinal Fluid from Pediatric Patients with Central Nervous System Cancer.Journal of proteome research · 2024Article
- Leptomeningeal Carcinomatosis in Early Gastric Cancer: A Case Report and Literature Review.Healthcare (Basel, Switzerland) · 2024Article
- Advancements in Cerebrospinal Fluid Biosensors: Bridging the Gap from Early Diagnosis to the Detection of Rare Diseases.Sensors (Basel, Switzerland) · 2024Review
- PMS2 amplification contributes brain metastasis from lung cancer.Biological procedures online · 2024Article
- Review
- Harnessing the power of Microscale AcoustoFluidics: A perspective based on BAW cancer diagnostics.Biomicrofluidics · 2024Article
- Treatment of brain metastases from non-small cell lung cancer: preclinical, clinical, and translational research.Frontiers in oncology · 2024Review
- Smart Nanozymes for Cancer Therapy: The Next Frontier in Oncology.Advanced healthcare materials · 2023Review
- Seq-ing the SINEs of central nervous system tumors in cerebrospinal fluid.Cell reports. Medicine · 2023Article
- Clinical Reasoning: New-Onset Diplopia and Headache in a Patient With Metastatic Breast Cancer.Neurology · 2023Article
- Exploring the role of cerebrospinal fluid as analyte in neurologic disorders.Future science OA · 2023Review
- Investigation of white blood cell characteristics in cerebrospinal fluid samples at pediatric brain tumor diagnosis.Journal of neuro-oncology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The spread of cancer into the central nervous system is a serious problem leading to neurological symptoms and rapid mortality. The current tools available for detecting the spread of cancer into the cerebrospinal fluid (CSF) are cytology, neurologic examination, and neuroimaging. All three of these methods can be applied in concert to reach a diagnosis, but they all suffer from a lack of sensitivity, leading to delays in treatment in many cases. An overview of research tools in the field of CSF cancer detection reveals a variety of promising technologies that can be used to answer questions about the biology of metastatic cancer and to develop more powerful clinical detection methods. Methods currently under investigation include new immunocytochemistry methods and flow cytometry for the in vitro detection of cells. Additionally, polymerase chain reaction, fluorescence in situ hybridization, capillary electrophoresis with laser-induced fluorescence, and mass spectrometry using matrix-assisted laser absorption-deionization time-of-flight and surface-enhanced laser desorption/ionization time-of-flight techniques are being tested for in vitro assessment of the non-cellular biomarkers in CSF. For in vivo detection of cancer in the CSF, research techniques include certain quantum dot platforms as well as magnetic iron oxide nanoparticles. As systemic therapies for cancer improve, the CNS is becoming a more common site of disease recurrence. This increases the importance of effective detection methods in the CSF, since early intervention can maximize therapeutic benefit. Furthermore, many cell-based detection methods can be combined with therapeutic agents to serve multiple medical functions through a common targeting system.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.